Amylyx Pharmaceuticals gets RELYVRIO FDA approval for ALS

TAGS

RELYVRIO FDA approval for ALS : Amylyx Pharmaceuticals has secured approval for (sodium phenylbutyrate and taurursodiol) from the (FDA) has approved for the treatment of (ALS) in adults.

RELYVRIO, which is an oral, fixed-dose medication, can be taken either as a monotherapy or with currently approved treatments for ALS, which is commonly called Lou Gehrig’s disease.

Joshua Cohen and — Co-CEOs of Amylyx Pharmaceuticals, commenting on RELYVRIO FDA approval for ALS, said: “Today’s FDA approval of RELYVRIO is an exciting milestone for the ALS community and is a major step toward achieving our mission to one day end the suffering caused by neurodegenerative diseases.

See also  Jardiance receives FDA approval to tackle kidney disease and cardiovascular risks

“We want to give a heartfelt thank you to the broader ALS community, including healthcare professionals and those living with ALS, for their guidance, support of our clinical programs, and for sharing their experiences with us. Their stories inspired us and helped our team to better understand the ALS clock, instilling in us a deep sense of urgency that will continue to drive us forward.”

RELYVRIO FDA approval for ALS was driven by the findings of the phase 2 CENTAUR clinical trial that featured 137 patients with the disease.

See also  OneSource Specialty Pharma reports stellar Q3FY25 earnings with 85% EBITDA growth, setting stage for expansion

Billy Dunn — FDA Center for Drug Evaluation and Research director of the Office of Neuroscience said: “This approval provides another important treatment option for ALS, a life-threatening disease that currently has no cure.

“The FDA remains committed to facilitating the development of additional ALS treatments.”

Previously called AMX0035 in the US, RELYVRIO considerably slowed the loss of physical function in ALS patients in the randomized, placebo-controlled clinical trial, said the Massachusetts-based Amylyx Pharmaceuticals.


Discover more from Business-News-Today.com

Subscribe to get the latest posts sent to your email.

CATEGORIES
TAGS
Share This